# AMPK/Energy Sensing Signaling: LKB1 Activation, Substrate Network, and Research Tools
For Research Use Only. Not for use in humans or animals.
---
Introduction
AMP-activated protein kinase (AMPK) is the cell's master energy sensor, a heterotrimeric serine/threonine kinase complex that monitors the ratio of AMP to ATP and responds to energetic stress by switching cells from anabolic to catabolic metabolism. Activated when cellular energy charge falls — during nutrient deprivation, hypoxia, exercise-induced metabolic stress, or mitochondrial dysfunction — AMPK phosphorylates a sprawling network of over 100 substrates that collectively suppress energy-consuming biosynthetic processes (lipid synthesis, protein synthesis via mTORC1) while activating energy-generating pathways (fatty acid oxidation, autophagy, glycolysis).
Beyond its canonical energy-sensing role, AMPK has emerged as a critical regulator of cell polarity, mitosis, autophagy initiation, circadian rhythm, and genome stability. The upstream kinase LKB1 (also known as STK11) is a potent tumor suppressor — biallelic loss of LKB1 underlies Peutz-Jeghers syndrome (PJS) and is found in ~15–30% of non-small cell lung cancers and numerous other malignancies. Loss of LKB1/AMPK signaling disconnects cells from energy surveillance, enabling unrestricted growth under nutrient-poor conditions characteristic of solid tumor microenvironments.
This review covers AMPK heterotrimer architecture, allosteric AMP/ADP activation, LKB1 and CaMKKβ upstream kinases, the AMPK substrate network (mTORC1, ULK1, ACC, PFKFB3, HMGCR, FOXO, YAP/TAZ), and validated research tools including AICAR, A-769662, compound 991, and pharmacological modulators of the pathway.
---
AMPK Heterotrimer Architecture
AMPK is obligately heterotrimeric, composed of one catalytic α subunit and regulatory β and γ subunits. Each subunit is encoded by multiple genes with tissue-specific expression patterns:
| Subunit | Genes | Key Domains | Function |
|---|---|---|---|
| α (catalytic) | PRKAA1 (α1), PRKAA2 (α2) | N-terminal kinase domain; autoinhibitory domain (AID); C-terminal β-subunit binding domain | Catalytic activity; T172 activation loop phosphorylation site |
| β (scaffold) | PRKAB1 (β1), PRKAB2 (β2) | N-terminal myristoylation (β1 only); carbohydrate-binding module (CBM); C-terminal αγ-subunit binding | Glycogen sensing (CBM); membrane targeting (myristoyl); scaffold function |
| γ (regulatory) | PRKAG1 (γ1), PRKAG2 (γ2), PRKAG3 (γ3) | Four cystathionine β-synthase (CBS) domains forming two Bateman domains; 3 adenine nucleotide binding sites | AMP/ADP/ATP competitive binding; allosteric activation; protection from dephosphorylation |
The 12 possible αβγ combinations (2×2×3) generate AMPK complexes with distinct subcellular localization, tissue distribution, and regulatory properties:
- •α1β1γ1: Ubiquitous; primarily cytoplasmic; major isoform in non-muscle tissues
- •α2β2γ1 and α2β2γ3: Skeletal and cardiac muscle-predominant
- •α2β1γ1 and α2β2γ2: Cardiac muscle-specific; PRKAG2 mutations (R302Q, N488I) cause hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome in research models
The γ Subunit Nucleotide Binding Sites
The γ subunit contains four CBS domains arranged as two Bateman domains, which together form three adenine nucleotide binding sites:
- •Site 1 (non-exchangeable): AMP permanently bound; structural role
- •Site 3 (inhibitory): ATP bound preferentially; active when energy charge is high
- •Site 4 (activating): AMP or ADP bound under energetic stress; promotes AMPK activation
When AMP:ATP ratio rises (energy stress), AMP competitively displaces ATP at site 4, triggering three synergistic AMPK activation mechanisms:
1. Allosteric activation: 5–10-fold increase in intrinsic kinase activity
2. Promotion of T172 phosphorylation: AMP binding promotes upstream kinase (LKB1) access to T172 in the activation loop
3. Protection from dephosphorylation: AMP (and ADP) binding prevents PP2Cα (PPM1A) from dephosphorylating phospho-T172, substantially prolonging kinase activity
ADP binding to site 4 provides similar (though somewhat weaker) protection from dephosphorylation, making AMP:ATP and ADP:ATP both relevant energy stress sensors.
---
Upstream Kinases: LKB1 and CaMKKβ
LKB1 (STK11): The Primary AMPK Kinase
LKB1 (Liver Kinase B1, encoded by STK11) is a serine/threonine kinase that functions in a constitutively active heterotrimeric complex with two pseudokinase/scaffold subunits:
- •STRAD α/β (STE20-related adapter proteins): Pseudokinases that bind LKB1 and promote its cytoplasmic localization, kinase activity, and substrate access. STRADα contains a degenerate ATP-binding site but lacks catalytic activity; it activates LKB1 by promoting a closed, active kinase conformation.
- •MO25 α/β (Mouse protein 25): Scaffolds that stabilize the LKB1-STRAD interaction and further enhance LKB1 kinase activity (~10-fold)
LKB1 phosphorylates AMPK at T172 in the activation loop, which is the primary activating phosphorylation event. LKB1 is constitutively active — its activity is not regulated by upstream signals but by AMP/ADP-dependent changes in T172 accessibility in the AMPK γ subunit. In resting cells, PP2Cα rapidly dephosphorylates T172; only when AMP binds the γ subunit does the net T172 phosphorylation state increase.
LKB1 also phosphorylates 12 additional AMPK-related kinases (ARKs): MARK1-4 (Microtubule-Associated Regulatory Kinases), BRSK1/2 (Brain-Specific Kinases, also called SAD kinases), NUAK1/2, SIK1-3 (Salt-Inducible Kinases), and SNRK. These ARKs regulate cell polarity, neuronal development, and metabolic gene expression, explaining why LKB1 loss has broad consequences beyond AMPK inactivation alone.
LKB1 as a tumor suppressor: Peutz-Jeghers syndrome (PJS) is caused by germline LKB1 mutations (hairy polyps in the GI tract; elevated cancer risk). In sporadic cancers, LKB1 is most frequently lost in:
- •Non-small cell lung adenocarcinoma (~15–30%, often co-occurring with KRAS mutations)
- •Cervical cancer (~20%)
- •Pancreatic cancer, melanoma
LKB1-null tumors are metabolically vulnerable and show dysregulation of mTORC1, autophagy, and mitochondrial biogenesis — all downstream of AMPK.
CaMKKβ (CAMKK2): Calcium-Dependent AMPK Activation
CaMKKβ (Calcium/calmodulin-dependent protein kinase kinase β) phosphorylates AMPK T172 in response to intracellular Ca²⁺ elevation, independently of AMP or ADP. CaMKKβ is the dominant AMPK kinase in neurons and is important in:
- •T cell receptor signaling (Ca²⁺ → CaMKKβ → AMPK → metabolic reprogramming)
- •Thrombin and VEGF receptor stimulation in endothelium (Ca²⁺ spike → CaMKKβ → AMPK → eNOS Ser1177 phosphorylation)
- •Hypothalamic leptin signaling (Ca²⁺ → CaMKKβ → AMPK suppression → reduced feeding, increased energy expenditure)
CaMKKβ-specific inhibitor STO-609 (IC50 ~120 nM for CaMKKβ; ~80× selective over CaMKKα) is a key tool for distinguishing Ca²⁺-dependent AMPK activation from AMP-dependent LKB1-mediated activation.
---
The AMPK Substrate Network
mTORC1 Inhibition: Two-Pronged Mechanism
AMPK suppresses mTORC1 signaling through two direct phosphorylation events:
1. TSC2 Phosphorylation (S1345, T1227, S1341):
AMPK phosphorylates Tuberous Sclerosis Complex 2 (TSC2/Hamartin) at multiple sites (most critical: S1345 in a consensus AMPK motif). TSC2 is a GAP (GTPase-activating protein) for the small GTPase RHEB; when TSC2 is active (and phosphorylated by AMPK at S1345), it converts RHEB from GTP-loaded (active) to GDP-loaded (inactive) form, thereby inactivating mTORC1.
2. Raptor Phosphorylation (S722, S792):
AMPK directly phosphorylates Raptor (Regulatory-associated protein of mTOR, mTORC1-specific scaffold) at S722 and S792. This phosphorylation creates 14-3-3 binding sites on Raptor, disrupting Raptor-mTOR interaction and reducing mTORC1 kinase activity. Raptor S792 phosphorylation is the most reliable AMPK activity readout for mTORC1 suppression in cell-based assays.
The net result of TSC2+Raptor phosphorylation is suppression of mTORC1-mediated protein synthesis (4E-BP1 and p70S6K remain unphosphorylated), reducing the cell's largest energy expenditure (protein synthesis accounts for ~30% of basal ATP consumption).
ULK1/ULK2: Autophagy Initiation
AMPK directly phosphorylates ULK1 (Unc-51-like autophagy activating kinase 1) at multiple activating sites: S317, S555, S777 (activating; promote ULK1 kinase activity and autophagy initiation) and S638 (mixed effects). This phosphorylation:
- •Activates ULK1 kinase activity
- •Stabilizes ULK1 by preventing proteasomal degradation
- •Recruits ULK1 to the pre-autophagosomal structure (PAS) through interaction with ATG13 and FIP200
Conversely, mTORC1 phosphorylates ULK1 at S757 (human ULK1), directly inhibiting ULK1 activity and blocking AMPK-ULK1 interaction. The AMPK-ULK1-mTOR triad creates a switch: high energy (active mTORC1) → ULK1 S757 phosphorylation → autophagy suppressed; low energy (active AMPK) → ULK1 S555 phosphorylation + mTORC1 suppression (ULK1 S757 dephosphorylation) → autophagy induction.
Fatty Acid Metabolism: ACC1 and ACC2
AMPK phosphorylates and inactivates both Acetyl-CoA Carboxylase isoforms:
- •ACC1 (ACACA, cytoplasmic): Catalyzes the first step of de novo lipogenesis: Acetyl-CoA → Malonyl-CoA. AMPK phosphorylates ACC1 at S79, inactivating it. Reduced ACC1 activity → decreased Malonyl-CoA → reduced fatty acid synthesis (anabolic suppression).
- •ACC2 (ACACB, mitochondria-associated): Generates Malonyl-CoA that allosterically inhibits CPT1 (Carnitine Palmitoyl Transferase 1, the rate-limiting enzyme for mitochondrial fatty acid import). AMPK phosphorylates ACC2 at S212, inactivating it. Reduced ACC2 → reduced Malonyl-CoA → CPT1 derepression → increased mitochondrial fatty acid import → enhanced β-oxidation (catabolic activation).
Phospho-ACC S79/S212 is one of the most widely used AMPK activity biomarkers in published research.
HMGCR: Cholesterol Synthesis
AMPK phosphorylates HMG-CoA Reductase (HMGCR) at S872, inactivating this rate-limiting enzyme of the mevalonate/cholesterol synthesis pathway. This reduces sterol and isoprenoid synthesis when energy is limiting — an important anabolic suppression mechanism given the high NADPH and ATP cost of cholesterol synthesis.
PFKFB3: Glycolysis Activation
To acutely increase ATP production during energy stress, AMPK activates glycolysis by phosphorylating PFKFB3 (6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3) at S461. PFKFB3 generates Fructose-2,6-bisphosphate (Fru-2,6-BP), a potent allosteric activator of Phosphofructokinase-1 (PFK-1), the rate-limiting enzyme of glycolysis. AMPK-mediated PFKFB3 phosphorylation and activation acutely boosts glycolytic flux to compensate for reduced mitochondrial output.
Transcriptional Regulation: PGC-1α and FOXO
AMPK also operates at the transcriptional level to promote long-term metabolic adaptation:
PGC-1α (PPARGC1A): AMPK phosphorylates PGC-1α at T177 and S538, activating this master transcriptional co-activator of mitochondrial biogenesis and fatty acid oxidation gene programs. PGC-1α co-activates PPARα, PPARγ, ERRα, and NRF1/2 transcription factors to induce mitochondrial gene expression. Importantly, AMPK-mediated PGC-1α phosphorylation synergizes with SIRT1-mediated PGC-1α deacetylation (as NAD⁺ levels rise during energy stress), creating a feedforward activation loop.
FOXO1/3 (Forkhead Box O transcription factors): AMPK phosphorylates FOXO1 (S413, S588) and FOXO3 (S399, S413, T449, S555) at sites distinct from the inhibitory AKT phosphorylation sites. AMPK-mediated FOXO phosphorylation promotes FOXO nuclear retention and activation of autophagy genes (BECN1, ATG4B, MAP1LC3B), further amplifying autophagy induction.
Additional Key Substrates
| Substrate | Phosphosite | Consequence |
|---|---|---|
| eEF2K | S398 | Activates eEF2K → eEF2 T56 phosphorylation → translational elongation slowdown |
| TXNIP | S308 | Destabilizes TXNIP → increases GLUT1/GLUT4 surface levels → glucose uptake |
| GEF-H1 | S885 | Inhibits RhoA GEF activity → cytoskeletal relaxation |
| BRAF | S365, S729 | Inhibits BRAF → reduces ERK signaling under energy stress |
| LATS1/2 | Multiple | Activates LATS → promotes YAP/TAZ cytoplasmic retention (energy stress → Hippo) |
| SNF1LK (SIK1) | T182 | Activates SIK1 → HDAC4/5 phosphorylation → CREB co-activator TORC2 nuclear export → CREB target gene suppression |
| p27/CDKN1B | T198 | Stabilizes p27 in cytoplasm → promotes autophagy; also maintains G1 arrest |
| FLCN (Folliculin) | S62 | Modulates Ragulator-mTORC1 lysosomal activation |
---
Research Tools for AMPK Signaling
Direct AMPK Activators
| Tool | Mechanism | Key Activity | Application |
|---|---|---|---|
| AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) | Cell-permeable AMP mimetic; converted to ZMP (AICA ribonucleotide) intracellularly; ZMP activates AMPK allosterically at γ site 4 | EC50 ~0.5–1 mM (cellular) | Most widely used AMPK activator; recapitulates AMP-mediated allosteric activation; does NOT work in cells lacking adenosine kinase |
| A-769662 | Direct allosteric activator at the ADaM (Allosteric Drug and Metabolite) site between α and β subunits; does not mimic AMP; activates β1-containing complexes preferentially | EC50 ~0.8 μM (AMPK α1β1γ1); ~100× selective over α2β2 | First synthetic direct AMPK activator; β1-subunit selective; widely used as positive control |
| Compound 991 (ex229) | ADaM site activator (like A-769662 but more potent and less β-isoform selective) | EC50 ~3 nM (biochemical); ~0.1–1 μM (cellular) | More potent than A-769662; activates both β1 and β2 complexes |
| MK-8722 | ADaM site activator (β1/β2 pan-activator) | EC50 ~5 nM | Highly potent pan-AMPK activator; used in metabolic research |
| PF-739 (PF-06685249) | ADaM site | Sub-nM potency | Pfizer-developed pan-AMPK activator tool compound |
| Metformin | Complex I inhibitor (indirect AMPK activation via AMP:ATP ratio elevation) | mM range (cellular) | Most used indirect activator; AMPK-dependent effects require LKB1 — LKB1-null cells respond differently; mitochondrial complex I inhibition → ↑AMP/ADP:ATP → AMPK |
| Phenformin | Complex I inhibitor (biguanide, more potent than metformin) | μM–mM range | More potent complex I inhibitor than metformin; used in research at lower concentrations |
| AMPK activator 7 (GSK-3b inhibitor — separate; do not confuse) | — | — | — |
| 2-Deoxyglucose (2-DG) | Hexokinase inhibitor → glycolysis blockade → ↑AMP:ATP | 1–10 mM | Indirect AMPK activator via ATP depletion; non-selective (also activates ER stress) |
| Oligomycin | ATP synthase inhibitor (Complex V) → ATP depletion → ↑AMP:ATP → AMPK | ~1–5 μg/mL | Potent indirect AMPK activator; non-selective metabolic tool |
| Rotenone | Complex I inhibitor | nM–μM | More potent than metformin; indirect AMPK via mitochondrial inhibition |
| IACS-010759 | Complex I inhibitor (clinical tool) | nM | MDACC-developed selective Complex I inhibitor for metabolic research |
AMPK Inhibitors
| Tool | Mechanism | Key Activity | Application |
|---|---|---|---|
| Compound C (dorsomorphin) | ATP-competitive AMPK inhibitor | IC50 ~109 nM (AMPK); also inhibits ALK2, BMP receptors, PDGFRβ | Most used AMPK inhibitor; NOTE: significant off-target effects (BMP pathway); use with caution and isogenic controls |
| SBI-0206965 | ULK1 inhibitor (downstream of AMPK) | IC50 ~108 nM (ULK1) | Not a direct AMPK inhibitor; used to dissect AMPK→ULK1→autophagy axis |
| STO-609 | CaMKKβ inhibitor (blocks Ca²⁺-dependent AMPK activation) | IC50 ~120 nM | Selectively blocks CaMKKβ→AMPK; does not affect LKB1-dependent AMPK activation |
Key Research Antibodies
| Antibody | Specificity | Application |
|---|---|---|
| Anti-phospho-AMPK T172 (40H9, CST) | Active AMPK α1/α2 | WB — canonical AMPK activation marker |
| Anti-AMPK α (total, D63G4, CST) | α1 + α2 pan | WB — loading control for T172 normalization |
| Anti-phospho-ACC S79 (D7D11, CST) | Active AMPK substrate | WB — downstream AMPK activity readout |
| Anti-ACC (total) | ACC1 + ACC2 | WB — loading control for phospho-ACC |
| Anti-phospho-Raptor S792 (2083, CST) | AMPK-mediated mTORC1 suppression | WB — mTORC1 inhibition by AMPK |
| Anti-phospho-ULK1 S555 (D1H4, CST) | AMPK-activated ULK1 | WB — autophagy initiation readout |
| Anti-phospho-ULK1 S757 (D7O6U, CST) | mTORC1-inhibited ULK1 | WB — mTOR activity on ULK1 |
| Anti-LKB1 (D60C5, CST) | Total LKB1 | WB — confirm LKB1 status (null vs. WT) |
| Anti-phospho-HMGCR S872 | AMPK substrate | WB — cholesterol synthesis suppression |
| Anti-phospho-PFKFB3 S461 | AMPK substrate | WB — glycolysis activation marker |
| Anti-phospho-p27 T198 | AMPK-stabilized p27 | WB |
| AMPK Alpha Kinase Assay Kit (CST) | Activity assay using SAMS peptide substrate | Kinase activity — gold standard for biochemical AMPK activity |
---
Experimental Protocols
Protocol 1: AMPK Activation Time Course — T172 Phosphorylation and Substrate Cascade
Objective: Characterize AMPK activation kinetics and downstream substrate phosphorylation after energy stress or direct AMPK activator treatment.
Materials: AICAR, A-769662, Compound 991, 2-DG, oligomycin; anti-phospho-AMPK T172, anti-AMPK α (total), anti-phospho-ACC S79, anti-ACC, anti-phospho-Raptor S792, anti-Raptor.
Procedure:
1. Seed cells in 6-well plates. For energy stress experiment: replace complete medium with glucose/serum-free HBSS or 0.1% glucose DMEM at t=0. For direct activator: add AICAR (0.5–2 mM) or A-769662 (10–100 μM) in complete medium.
2. Collect cells at 0, 15, 30, 60, 120, 240 min. Lyse in RIPA + phosphatase inhibitors (PhosSTOP essential).
3. Western blot: probe phospho-AMPK T172 (expect rapid activation at 15–30 min, maximal at 60 min for energy stress; more sustained for direct activators). Total AMPK α as loading control.
4. Downstream cascade: phospho-ACC S79 (AMPK substrate; should parallel T172 with slight lag), phospho-Raptor S792 (AMPK-mediated mTORC1 suppression).
5. LKB1 dependency control: Compare isogenic LKB1-WT vs. LKB1-null cells (e.g., A549 LKB1-null vs. A549 with re-expressed LKB1). AICAR/2-DG-induced AMPK activation requires LKB1; CaMKKβ-dependent activation (ionomycin, 1 μM Ca²⁺ ionophore, 10 min) should be preserved in LKB1-null cells.
6. CaMKKβ contribution: Treat cells with STO-609 (10 μM, 30 min pretreatment) then ionomycin (1 μM, 10 min) or AICAR (1 mM, 1h). STO-609 should block ionomycin-induced phospho-T172 but not AICAR-induced T172 phosphorylation (which goes through LKB1).
Expected outcomes: Energy stress → phospho-T172 peak at 30–60 min, sustained for 2–4h; phospho-ACC S79 parallels T172; phospho-Raptor S792 elevates at 60–120 min as mTORC1 is suppressed. A-769662 (50 μM) → faster and more sustained T172 phosphorylation than energy stress alone. LKB1-null cells: no AICAR response; preserved ionomycin response. STO-609 blocks ionomycin- but not AICAR-induced AMPK activation.
---
Protocol 2: AMPK-mTORC1 Axis — Autophagy Induction via ULK1
Objective: Dissect AMPK→ULK1→autophagy cascade and its opposition by mTORC1→ULK1 inhibitory phosphorylation.
Materials: AICAR, Compound 991, rapamycin (mTORC1 inhibitor), SBI-0206965 (ULK1 inhibitor), MRT68921 (dual ULK1/2 inhibitor), anti-phospho-ULK1 S555 (AMPK site), anti-phospho-ULK1 S757 (mTOR site), anti-LC3B (autophagy marker), anti-p62/SQSTM1, bafilomycin A1 (lysosomal acidification inhibitor, to block autophagic flux and accumulate LC3B-II).
Procedure:
1. Treat cells with: (a) AICAR (1 mM), (b) Compound 991 (1 μM), (c) rapamycin (100 nM), (d) AICAR + rapamycin (combination), (e) AICAR + SBI-0206965 (2 μM, ULK1 inhibitor), (f) full starvation (HBSS, 2h) as positive control. Treat for 2h.
2. Western blot: Probe for phospho-ULK1 S555 (AMPK→ULK1 activation; should increase with AICAR/Compound 991), phospho-ULK1 S757 (mTOR→ULK1 inhibition; should decrease with rapamycin and AICAR).
3. LC3B flux assay: Include parallel wells with bafilomycin A1 (100 nM) added 2h before lysis to block lysosomal degradation. Probe for LC3B-I (18 kDa) and LC3B-II (16 kDa, lipidated form). Increased LC3B-II in bafilomycin-treated cells vs. vehicle = autophagic flux; increased LC3B-II in AICAR + bafilomycin vs. vehicle + bafilomycin = AMPK-induced increase in autophagy.
4. p62 degradation: Sustained autophagy (>6h AICAR or starvation) leads to p62/SQSTM1 degradation (p62 is a selective autophagy cargo receptor). Probe for p62 loss as evidence of autophagic cargo clearance. Bafilomycin blocks p62 degradation.
5. ULK1 dependency: SBI-0206965 (ULK1 inhibitor, 2 μM) co-treated with AICAR should reduce LC3B-II accumulation, confirming AMPK acts through ULK1 for autophagy induction.
Expected outcomes: AICAR/Compound 991 → increased phospho-ULK1 S555; rapamycin → decreased phospho-ULK1 S757. Combination (AICAR + rapamycin) → synergistic autophagy induction (both ULK1 activation and mTOR-mediated inhibition removed). Bafilomycin experiment: AICAR significantly increases LC3B-II accumulation above bafilomycin-only baseline. SBI-0206965 attenuates AICAR-induced LC3B-II accumulation.
---
Protocol 3: AMPK-Dependent Lipid Metabolism — ACC Phosphorylation and Fatty Acid Oxidation
Objective: Quantify AMPK-mediated inhibition of de novo lipogenesis (via ACC phosphorylation) and activation of mitochondrial fatty acid oxidation.
Materials: AICAR, A-769662, Compound 991, TOFA (ACC inhibitor, positive control for de novo lipogenesis block), etomoxir (CPT1 inhibitor, blocks fatty acid oxidation), [¹⁴C]acetic acid or BODIPY-C12 fatty acid for lipid synthesis/oxidation assays, anti-phospho-ACC S79, Oil Red O (neutral lipid staining).
Procedure:
1. Phospho-ACC readout: Treat cells with AICAR (0.5–2 mM), A-769662 (10–100 μM), or Compound 991 (0.1–1 μM) for 1h. Western blot for phospho-ACC S79 and total ACC. Expect dose-dependent phospho-ACC increase.
2. De novo lipogenesis (DNL) assay: Pre-treat cells 30 min with AICAR (1 mM) or TOFA (positive control, 5 μg/mL). Add [1-¹⁴C]acetic acid (5 μCi/well) for 4h in the continued presence of inhibitors. Extract total lipids (Folch extraction: chloroform:methanol 2:1). Count ¹⁴C incorporation in lipid fraction by scintillation counter. AMPK activation should reduce ¹⁴C-lipid incorporation by 30–70%.
3. Alternative lipid synthesis assay (fluorescent): Use BODIPY-C12 (fluorescent fatty acid analog) to label newly synthesized lipids. Image by fluorescence microscopy + quantify fluorescence per cell. AICAR/A-769662 → reduced BODIPY-C12 neutral lipid accumulation.
4. Fatty acid oxidation assay: Treat cells with AICAR (1 mM, 1h) or vehicle. Add [1-¹⁴C]palmitic acid (0.1 mM, 1 μCi/well, complexed to BSA) for 2h. Collect gas phase ¹⁴CO₂ in NaOH-soaked filter paper placed above sealed culture well. Liquid phase ¹⁴C-labeled acid-soluble metabolites (ASM, incomplete oxidation products) in medium. ¹⁴CO₂ + ASM = total β-oxidation rate. AMPK activation should increase β-oxidation; etomoxir (200 μM) should block CPT1-dependent mitochondrial oxidation.
5. Oil Red O staining: After 48h AICAR treatment in lipogenic conditions (high glucose + insulin), fix cells with 4% PFA, stain with Oil Red O. Quantify neutral lipid (triglyceride) accumulation. AMPK activation should reduce lipid droplet accumulation.
---
Protocol 4: AMPK-LATS-YAP Cross-Talk in Energy Stress
Objective: Assess AMPK-dependent Hippo pathway activation under nutrient stress, with YAP/TAZ cytoplasmic relocalization as the functional readout.
Materials: AICAR, A-769662, AICAR + Compound C (AMPK inhibitor control), anti-phospho-LATS1 T1079, anti-LATS1, anti-phospho-YAP S127, anti-YAP, DAPI, fluorescence microscopy for YAP IF.
Procedure:
1. Treat sparse cells (nuclear YAP under basal conditions) with: (a) vehicle (DMSO), (b) AICAR (2 mM, 2h), (c) A-769662 (50 μM, 2h), (d) AICAR + Compound C (10 μM, 1h pretreatment), (e) glucose starvation (HBSS, 2h).
2. Western blot: Phospho-AMPK T172 (confirm AMPK activation), phospho-LATS1 T1079 (AMPK→LATS activation), phospho-YAP S127 (LATS-mediated YAP inactivation). Include total AMPK, LATS1, YAP.
3. Immunofluorescence: For YAP nuclear-cytoplasmic localization, fix cells and perform anti-YAP IF. Score nuclear:cytoplasmic ratio. Energy stress should shift YAP to cytoplasm in a LATS-dependent manner.
4. Target gene suppression: After 6h AICAR treatment, measure CTGF and CYR61 mRNA by RT-qPCR. Energy stress-induced AMPK activation → LATS activation → YAP cytoplasmic → CTGF/CYR61 suppression.
5. LATS dependency control: Use LATS1/2 double knockdown cells (siRNA or CRISPR) to confirm that AMPK-induced YAP phosphorylation and cytoplasmic redistribution require LATS1/2. In LATS1/2 DKO cells, AICAR should still activate AMPK (T172+) but should not increase phospho-YAP S127.
---
Protocol 5: AMPK Activity Assay — SAMS Peptide Phosphorylation
Objective: Directly measure AMPK kinase activity from cell/tissue lysates using the SAMS peptide substrate assay.
Materials: SAMS peptide (HMRSAMSGLHLVKRR — the ACC-derived AMPK substrate peptide; commercially available), [γ-³²P]-ATP or non-radioactive ADP-Glo assay system, anti-AMPK α (for IP), protein A/G beads, AMPK lysis buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 50 mM NaF, 5 mM Na-pyrophosphate, 1 mM EDTA, 1 mM DTT, 0.1% Brij-35, phosphatase inhibitors), AMP (to boost activity during assay).
Procedure:
1. Treat cells under energy stress (AICAR 1 mM, 1h) or vehicle. Lyse 3×10⁷ cells in AMPK lysis buffer, clarify by centrifugation.
2. AMPK immunoprecipitation: Add anti-AMPK α1 + anti-AMPK α2 (2 μg each) to 500 μg total protein lysate. Rotate overnight at 4°C. Capture with 40 μL Protein A/G beads (2h). Wash 3× lysis buffer, 2× kinase assay buffer (40 mM Hepes pH 7.4, 80 mM NaCl, 8% glycerol, 5 mM MgCl₂, 200 μM AMP, 200 μM DTT).
3. Kinase assay: Add 25 μL kinase reaction mix per IP (kinase assay buffer + 200 μM SAMS peptide + 200 μM [γ-³²P]-ATP, ~1000 cpm/pmol). Incubate 30°C × 30 min with occasional mixing.
4. Spot assay: Apply 40 μL onto P81 phosphocellulose paper squares. Wash 3× with 1% phosphoric acid (5 min each), once with acetone. Dry and count bound radioactivity by scintillation counting. Subtract blank (no cell lysate control). Report as pmol phosphate incorporated per min per mg total protein.
5. Non-radioactive alternative: Use ADP-Glo Kinase Assay (Promega) with SAMS peptide and unlabeled ATP (luminescent ADP detection). Perform IP-kinase assay as above but use ADP-Glo reagents per manufacturer protocol.
Expected outcomes: AICAR-treated cell lysates: 3–10-fold higher SAMS peptide phosphorylation vs. vehicle-treated. LKB1-null cells show minimal AICAR response. Direct addition of AMP (500 μM) to the kinase assay buffer should partially activate basal AMPK activity even from vehicle-treated lysates (allosteric activation in vitro).
---
Pathway Integration
AMPK-SIRT1-PGC-1α Axis
NAD⁺ levels rise during energy stress (as NADH is consumed by mitochondria and NAD⁺ salvage pathways are upregulated). Elevated NAD⁺ activates SIRT1 (NAD⁺-dependent deacetylase), which deacetylates PGC-1α at K183, K253, K292, K346. AMPK-mediated PGC-1α phosphorylation (T177, S538) and SIRT1-mediated deacetylation are synergistic — both events are needed for full PGC-1α transcriptional activity. This AMPK-SIRT1-PGC-1α axis links acute energy sensing to long-term mitochondrial biogenesis.
AMPK-Autophagy-mTOR Feedback
A critical design principle: autophagy triggered by AMPK (via ULK1 activation) generates free amino acids from protein degradation, which reactivate mTORC1 (amino acids activate the Ragulator-RagGTPase-mTORC1 pathway on lysosomal membranes). This creates a feedback loop where AMPK-initiated autophagy eventually restores amino acid pools and reactivates mTORC1, which then suppresses further ULK1 activity — a self-limiting autophagic response.
AMPK and Cell Cycle Arrest
Under severe energy stress, AMPK promotes cell cycle arrest via:
- •p27/CDKN1B stabilization (phospho-T198; p27 retained in cytoplasm as pro-autophagic signal)
- •BRAF suppression (reduces cyclin D1 induction)
- •p53 stabilization (AMPK phosphorylates p53 at S15, contributing to p53 activation)
- •Indirect CDK inhibition via mTORC1 suppression (reduced cyclin D/E translation)
---
References
1. Hardie DG, Ross FA, Hawley SA. "AMPK: a nutrient and energy sensor that maintains energy homeostasis." Nat Rev Mol Cell Biol. 2012;13(4):251-262. PMID: 22436748
2. Shaw RJ, et al. "The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress." Proc Natl Acad Sci USA. 2004;101(10):3329-3335. PMID: 14985505
3. Woods A, et al. "Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells." Cell Metab. 2005;2(1):21-33. PMID: 16054096
4. Gwinn DM, et al. "AMPK phosphorylation of raptor mediates a metabolic checkpoint." Mol Cell. 2008;30(2):214-226. PMID: 18439900
5. Inoki K, Zhu T, Guan KL. "TSC2 mediates cellular energy response to control cell growth and survival." Cell. 2003;115(5):577-590. PMID: 14651849
6. Kim J, et al. "AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1." Nat Cell Biol. 2011;13(2):132-141. PMID: 21258367
7. Fullerton MD, et al. "Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin." Nat Med. 2013;19(12):1649-1654. PMID: 24185692
9. Foretz M, et al. "Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state." J Clin Invest. 2010;120(7):2355-2369. PMID: 20577053
10. Mo JS, et al. "Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway." Nat Cell Biol. 2015;17(4):500-510. PMID: 25751139
11. Mihaylova MM, Shaw RJ. "The AMPK signalling pathway coordinates cell growth, autophagy and metabolism." Nat Cell Biol. 2011;13(9):1016-1023. PMID: 21892142
12. Herzig S, Shaw RJ. "AMPK: guardian of metabolism and mitochondrial homeostasis." Nat Rev Mol Cell Biol. 2018;19(2):121-135. PMID: 28974774
---
This article is intended for research use only (RUO). All compounds, reagents, and biological tools discussed herein are for in vitro laboratory investigation. No information in this article constitutes medical advice, dosing guidance for human or animal use, or clinical protocol recommendations.